CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer-Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data

被引：2
|
作者：
Guarneri, V.
Frassoldati, A.
Cagossi, K.
Bottini, A.
Michelotti, A.
Cavanna, L.
Jovic, G.
Piacentini, F.
Oliva, C.
Conte, P. F.
机构：
[1] Modena Univ Hosp, Modena, Italy
[2] Ramazzini Hosp, Carpi, Italy
[3] Ist Ospitalieri, Cremona, Italy
[4] St Chiara Univ Hosp, Pisa, Italy
[5] Hosp Piacenza, Piacenza, Italy
[6] GlaxoSmithKline, Greenford, Middx, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
580
引用
收藏
页数：1
相关论文
共 47 条
  • [1] Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer
    V Guarneri
    A Frassoldati
    F Piacentini
    K Cagossi
    L Cavanna
    A Michelotti
    G Jovic
    S Giovannelli
    G Ficarra
    C Oliva
    P Conte
    Breast Cancer Research, 9
  • [2] Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer
    Guarneri, V.
    Frassoldati, A.
    Piacentini, F.
    Cagossi, K.
    Cavanna, L.
    Michelotti, A.
    Jovic, G.
    Giovannelli, S.
    Ficarra, G.
    Oliva, C.
    Conte, P.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [3] Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial
    Guarneri, V.
    Frassoldati, A.
    Bottini, A.
    Cagossi, K.
    Cavanna, L.
    Ravaioli, A.
    Amadori, D.
    Giardina, G.
    Oliva, C.
    Conte, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial)
    Guarneri, Valentina
    Frassoldati, Antonio
    Piacentini, Federico
    Jovic, Gordana
    Giovannelli, Simona
    Oliva, Cristina
    Conte, PierFranco
    CLINICAL BREAST CANCER, 2008, 8 (02) : 192 - 194
  • [5] Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial)
    Guarneri, V.
    Frassoldati, A.
    Bottini, A.
    Generali, D. G.
    Cagossi, K.
    Artioli, F.
    Bisagni, G.
    Boni, C.
    Ravaioli, A.
    Amadori, D.
    Musolino, A.
    Cavanna, L.
    Untch, M.
    Orlando, L.
    Giardina, G.
    Piacentini, F.
    Tagliafico, E.
    Bagnalasta, M.
    D'Amico, R.
    Conte, P. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer.
    Guarneri, V.
    Frassoldati, A.
    Ficarra, G.
    Maiorana, A.
    Bettelli, S.
    Bottini, A.
    Cagossi, K.
    Bisagni, G.
    Ravaioli, A.
    Amadori, D.
    Musolino, A.
    Cavanna, L.
    Orlando, L.
    Giardina, G.
    Piacentini, F.
    Bagnalasta, M.
    Conte, P.
    CANCER RESEARCH, 2011, 71
  • [7] Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
    Guarneri, Valentina
    Frassoldati, Antonio
    Bottini, Alberto
    Cagossi, Katia
    Bisagni, Giancarlo
    Sarti, Samanta
    Ravaioli, Alberto
    Cavanna, Luigi
    Giardina, Giovanni
    Musolino, Antonino
    Untch, Michael
    Orlando, Laura
    Artioli, Fabrizio
    Boni, Corrado
    Generali, Daniele Giulio
    Serra, Patrizia
    Bagnalasta, Michela
    Marini, Luca
    Piacentini, Federico
    D'Amico, Roberto
    Conte, PierFranco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1989 - 1995
  • [8] Safety and Activity Report of a Randomized Phase II Trial of Preoperative Anthracycline-Based Chemotherapy Plus Lapatinib, Trastuzumab or Both in HER2 Positive Breast Cancer: CHERLOB Trial
    Guarneri, V
    Frassoldati, A.
    Bottini, A.
    Cagossi, K.
    Piacentini, F.
    Ravaioli, A.
    Cavanna, L.
    Amadori, D.
    Bisagni, G.
    Giardina, G.
    Conte, P.
    CANCER RESEARCH, 2009, 69 (24) : 568S - 569S
  • [9] Original Research Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial
    Guarneri, Valentina
    V. Dieci, Maria
    Griguolo, Gaia
    Miglietta, Federica
    Girardi, Fabio
    Bisagni, Giancarlo
    Generali, Daniele G.
    Cagossi, Katia
    Sarti, Samanta
    Frassoldati, Antonio
    Gianni, Lorenzo
    Cavanna, Luigi
    Pinotti, Graziella
    Musolino, Antonino
    Piacentini, Federico
    Cinieri, Saverio
    Prat, Aleix
    Conte, PierFranco
    EUROPEAN JOURNAL OF CANCER, 2021, 153 : 133 - 141
  • [10] Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer
    Musolino, Antonino
    Guarneri, Valentina
    Naldi, Nadia
    Bortesi, Beatrice
    Boggiani, Daniela
    Sgargi, Paolo
    Generali, Daniele G.
    Piacentini, Federico
    Dieci, Maria V.
    Ambroggi, Massimo
    Cagossi, Katia
    Gianni, Lorenzo
    Sarti, Samanta
    Bisagni, Giancarlo
    Frassoldati, Antonio
    Conte, Pierfranco
    Ardizzoni, Andrea
    CANCER RESEARCH, 2015, 75
12345